Abstract
Alzheimer’s disease (AD), the most prevalent form of dementia, is characterized by progressive cognitive decline and neuropathological hallmarks such as amyloid-β plaques and tau neurofibrillary tangles. Traditional symptomatic treatments have offered limited efficacy, prompting the development of targeted therapies aimed at modifying disease progression. This article explores key advancements in Alzheimer’s targeted therapies, focusing on anti-amyloid agents, tau-targeted treatments, and gene-based interventions. Despite challenges in clinical translation, recent FDA approvals and ongoing trials indicate a paradigm shift toward disease-modifying strategies that could significantly alter the future of Alzheimer’s care.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.